Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including ...

Following a turbulent period that left many shareholders disappointed, Novo Nordisk enters 2026 at a pivotal juncture. The pharmaceutical giant saw nearly half of its market capitalization evaporate ...

The Punjab Government's relentless campaign against narcotics reached a new milestone as over 1,000 officers executed ...

As an aside, see 3 Risks That Can Make UnitedHealth Stock Unattractive. Additionally, see: MSFT Stock A Winner In 2026? JNJ ...

Industry analysis examines published SURMOUNT clinical trial data, evolving FDA compounding guidance, and telehealth access ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Novo Nordisk just got a big win from the FDA, and it could change the weight-loss medicine industry again. Novo has a new ...

Each day at 9:30 a.m., the kitchen of Chenjiuye noodle shop slowly comes to life. Zhonghang and his girlfriend are the first ...

Appetite-suppressing GLP-1 tablets become accessible in January, and manufacturers and fast-food eateries may be pushed to alter more of their goods.

The competitive landscape for obesity medications is undergoing a significant shift. Eli Lilly now confronts intensified ...

On Monday, the Food and Drug Administration approved a pill version of Wegovy, Novo Nordisk’s wildly popular weight loss drug ...

A DAILY weight loss pill that helped patients shed up to 20 per cent of their body weight in trials has been given the green ...